Diagnostics Solutions Strategic Priorities
Improving disease management to reduce strokes
Innovation on-market and pipeline for atrial fibrillation
Screening
NT-proBNP1
and handheld ECG
Diagnosis
ECG & new
biomarkers³
Risk stratification
ABC risk scores
with GDF-15 and clinical
information
Therapy selection
Integrated digital
solutions; ABC scores
Launch in 20212
Research ongoing³
On-market4
+29% AFib
patients identified
Identify patients
at high risk for Afib and
recurrence of AFib³
Best available
predictors of stroke and bleeding
risk4
Clinical trials (RCT) 5,6
Roche
Personalised risk assessment for
better outcomes:
Reduce stroke risk 5,6
Increase therapy adherence5
AFib: Atrial Fibrillation; ECG: Electrocardiogram; (N)OAC: (Novel) Oral Anticoagulant ; 1 Article: Gudmundsdottir KK et al, EP Europace 2020, 22: 24; 2 Launch new intended use planned for 2021; 3 New biomarker research
projects: Chua W et al., Lancet 2021 (1-Feb-2021, http://dx.doi.org/10.2139/ssrn.3777185), Reyat JS et al, JCI Insight 2020,15: e139179 (and 7 new Roche patents in 2020); 4 Hijazi Z et al, Lancet. 2016; 387: 2302; 5 Clinical
outcome trial ongoing (NCT03753490, ABC-AF); 6 Clinical outcome trial ongoing (NCT02743416, STROKESTOP-II)
59View entire presentation